헤더 로고

• All
• Day 1: March 26 (Thu)
• Day 2: March 27 (Fri)
• Day 3: March 28 (Sat)

Day 1: March 26 (Thu)

• Advances and Insights in Molecular Monitoring for Myeloproliferative Neoplasms Hsin-An Hou
  National Taiwan University Hospital, Taiwan CV
• Recent Therapeutic Advances in Early MF Winnie Teo
  Alexandra Hospital, Singapore CV
• Optimizing Treatment Strategies in Higher MF and Beyond Sung-Eun Lee
  College of Medicine, The Catholic University of Korea, Korea CV

Day 1: March 26 (Thu)

• Recent Advances in the Diagnosis and Management of Acquired Hemophilia A Shin Young Hyun
  Yonsei University College of Medicine, Korea CV
• Clinical Advances and Challenges in Gene Therapy Ben Samelson-Jones
  The Children's Hospital of Philadelphia, USA CV
• Role of Bispecific Antibody in Hemophilia Claude Négrier
  University of Lyon, France CV

Day 1: March 26 (Thu)

• Integration of MRD and Genetics as a Therapeutic Guidepost in ALL Anthony Moorman
  Newcastle University, UK CV
• Modern Immunotherapeutics in B-ALL: BiTEs, ADCs, and Beyond Jae-Ho Yoon
  College of Medicine, The Catholic University of Korea, Korea CV
• Optimizing Frontline Therapy in Ph+ ALL: The Role of Ponatinib and Beyond Nicholas J. Short
  The University of Texas MD Anderson Cancer Center, USA CV

Day 1: March 26 (Thu)

• Mantle Cell Lymphoma Jaewon Hyung
  University of Ulsan College of Medicine, Korea CV
• Chronic Lymphocytic Leukemia Jongheon Jung
  National Cancer Center, Korea CV
• Marginal Zone Lymphoma Sang-A Kim
  Seoul National University College of Medicine, Korea

Day 1: March 26 (Thu)

• Leukemic Stem Cells in 2026: Hierarchies, Heterogeneity, and Therapeutic Resistance John E. Dick
  University Health Network, Canada CV

Day 1: March 26 (Thu)

• Targeted Treatment of Aggressive B-cell Lymphomas Wyndham H. Wilson
  National Cancer Institute, USA CV

Day 1: March 26 (Thu)

• Integrating Comprehensive Geriatric Assessment into Hematology Practice: Identifying Frailty and Optimizing Care for Older Adults Jung-Yeon Choi
  Seoul National University Bundang Hospital, Korea CV
• Redefining Risk in Elderly AML: The GA Approach Byung Sik Cho
  College of Medicine, The Catholic University of Korea, Korea CV
• Psycho-oncological Interventions in Geriatric Hematology: Enhancing Quality of Life Juhee Cho
  Samsung Advanced Institute for Health Sciences & Technology, Korea

Day 1: March 26 (Thu)

• Affinity Tuning and Cytokine Modulation in CAR-T and CAR-NK Therapy Challice Bonifant
  Johns Hopkins University School of Medicine, USA CV
• Lessons from Hemophagocytic Lymphohistiocytosis: Taming the Cytokine Storm in CAR-T Cell Therapy Michael B. Jordan
  Cincinnati Children’s Hospital Medical Center, USA
• Myeloid Cells as Mediators of Cell Therapy: From Suppression to Activations Seunghee Kim-Schulze
  Icahn School of Medicine at Mount Sinai, USA CV

Day 1: March 26 (Thu)

• FLT3 Positive AML Ik-Chan Song
  Chungnam National University College of Medicine, Korea CV
• B-cell ALL with High Risk Features in Adults Dong Won Baek
  Kyungpook National University School of Medicine, Korea CV
• Understanding and Clinical Approach to Early T-cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) Hee Young Ju
  Sungkyunkwan University School of Medicine, Korea CV

Day 1: March 26 (Thu)

• Insights into DDX41 Mutations: Relatively Common Genetic Aberrations in Korean MDS Patients Hongtae Kim
  Ulsan National Institute of Science and Technology, Korea CV
• Few Drug Approvals in MDS: Lessons and Insights from a Decade of Clinical Trials Maximilian Stahl
  Yale University School of Medicine, USA CV
• Clinical Approach to Relapsed or Refractory Lower-Risk Myelodysplastic Syndromes Valeria Santini
  University of Florence, Italy CV

Day 1: March 26 (Thu)

• Recent Advances in the Genetics of Telomere Biology Disorders Sharon A. Savage
  National Institutes of Health, USA
• Role of Clonal Hematopoiesis in the Short Telomere Syndromes Kristen E. Schratz
  Johns Hopkins University School of Medicine, USA CV
• Dyskeratosis Congenita and Related Telomere Biology Disorders Inderjeet Dokal
  Queen Mary University of London, UK CV

Day 1: March 26 (Thu)

• Next-Generation Effector Cells in Myeloma Immunotherapy Hyunsoo Cho
  Seoul National University Hospital, Korea CV
• Natural Killer Cell-Based Immunotherapy in Multiple Myeloma Seung-Hwan Lee
  University of Ottawa, Canada CV
• Resistant Mechanisms and Newer Immunogenic Targets in Relapsed or Refractory Multiple Myeloma Marta Chesi
  Mayo Clinic, USA CV

Day 1: March 26 (Thu)

• Procedures and Interpretation of Bone Marrow Examination Seung Yeob Lee
  Jeonbuk National University Medical School, Korea CV
• Diagnostic and Monitoring Approaches Focused on Minimal Residual Disease Miyoung Kim
  University of Ulsan College of Medicine, Korea
• Blood Bank Testing before and after Hematopoietic Stem Cell Transplantation Dong Wook Jekarl
  College of Medicine, The Catholic University of Korea, Korea CV